荣昌生物官方网站首页
Products
Telitacicept
Telitacicept (RC18) is a first-in-class TACI-Fc fusion protein for injection developed by RemeGen which targets two important cell-signaling molecules, B-cell lymphocyte stimulator (BLyS) and A proliferation inducing ligand (APRIL). Seven indications of Telitacicept are in commercial or clinical trials stage in autoimmune diseases area and the treatment of systemic lupus erythematosus(SLE) has been granted approval by NMPA and also been included in the National Reimbursement Drug List (NRDL).
Disitamab Vedotin
Disitamab Vedotin （RC48） is the first Chinese ADC drug created and developed by RemeGen to receive breakthrough designations in both the United States and China, the treatment of gastric cancer had been granted approval by NMPA in 2021 and also been included in the National Reimbursement Drug List (NRDL), the indication of urothelial carcinoma had been granted approval by NMPA in the same year.
Product Pipeline
Leveraging our strong abilities of discovery, research and development, we have discovered and developed more than 20 drug candidates.
RemeGen RC118 phase I clinical study shows favorable safety and tolerability
RemeGen receives approval to conduct a global multicenter phase 3 clinical trial of Telitacicept for
RemeGen gains FDA’s Orphan Drug designation for Telitacicept in myasthenia gravis
Disitamab Vedotin appeared on ASCO 2022 meeting and brought exciting clinical data on urothelial car
New clinical data of Telitacicept was published in Lupus, for the indication of children's systemic
RemeGen has successfully completed A-share listing IPO, starting a new era of “A+H”
STAR Market stock code：
荣昌生物：688331.SHHKEX stock code：
荣昌生物：09995.HK- Announcements and Notices
- Financial Reports
- Listing Documents
-
11 2023.09
[Final Results / Other - Miscellaneous] SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO 2022 ANNUAL REPORT
-
06 2023.09
Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023
-
04 2023.09
[Overseas Regulatory Announcement - Corporate Governance Related Matters / Overseas Regulatory Announcement-Other] An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
-
04 2023.09
[Change in Directors or of Important Executive Functions or Responsibilities / Change in Company Secretary] RESIGNATION OF CHIEF FINANCIAL OFFICER AND JOINT COMPANY SECRETARY
-
22 2023.08
[Other - Business Update] VOLUNTARY ANNOUNCEMENT-RESULTS OF PHASE III STUDY ON TELITACICEPT FOR TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN CHINA
-
22 2023.08
[Interim Results / Revision of Information in Published Preliminary Results] CLARIFICATION ANNOUNCEMENT IN RELATION TO THE INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
-
21 2023.08
[Interim Results] INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
-
02 2023.08
Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023
-
03 2023.07
Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2023
-
01 2023.06
Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2023
-
05 2023.05
Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023
-
14 2023.04
[Overseas Regulatory Announcement - Other] An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
58 Beijing Middle Road, Yantai Shandong, China.
-
- Company Wechat